Azathioprine drug has been in clinical use since its discovery in 1957 in which it was used as a chemotherapy drug. It produces a biological metabolite known as 6-mercaptopurine which is a metabolically active form and it acts as an immunosuppressant. In regard to pharmacokinetics of azathioprine, this drug functions by inhibiting purine synthesis in the body leading to the impairment of cellular proliferation because there is lack of adequate DNA molecules for the formation of new cell. In particular, immune cells are prevented from multiplication owing to the inhibition of purine synthesis in the lymphoid tissues. It has been found out that the inhibition of DNA synthesis hinders nucleotide salvage process which ensures continuous production of lymphocytes for immune responses, especially during infections (Desler, Lykke & Rasmussen, 2010). Therefore, this research paper focuses on azathioprine genetic polymorphisms.
Table of Contents
1. Introduction
2. Clinical Uses of Azathioprine
3. Pertinent Genetic Variability
4. Functional Effect of Genetic Variability
5. Population Prevalence
6. Clinical Relevancy
Research Objectives and Key Topics
This paper examines the clinical implications of genetic polymorphisms in patients undergoing azathioprine treatment, specifically focusing on how variations in metabolic enzymes affect drug toxicity, efficacy, and patient safety.
- Mechanism of action of azathioprine and its metabolic pathways
- Role of thiopurine methyltransferase (TPMT) genetic variants
- Correlation between enzyme polymorphisms and adverse clinical effects
- Ethnic trends in the prevalence of specific genetic variants
- Clinical relevance of pharmacogenetics in managing autoimmune diseases and leukemia
Excerpt from the Book
Pertinent Genetic Variability
Despite the potency of azathioprine in treating autoimmune diseases and its use in immunosuppressive therapy, the drug’s mechanism of action has been found to be linked to pertinent genetic variability. It is believed that aspect of azathioprine’s genetic variability has compromised its clinical use in the treatment of an array of autoimmune diseases, which are managed under long-term strategies.
Ordinarily, azathioprine metabolism relies on genetic polymorphism of a number of enzymes inside the body of humans. However, inosine triphosphate pyrophosphatase (ITPA) and thiopurine S-methyltransferase have been identified to be the most significant enzymes involved in the azathioprine’s metabolism. Research shows that genetic polymorphisms are the most principal issues related to the adverse clinical effects associated with azathioprine treatment among different patients, although the trends of genetic polymorphism exhibit ethnic links (Torkamani, 2013).
Currently, thiopurine methyltransferase (TPMP) has been found to have 28 variant alleles. However, only a few of the 28 variant alleles have been identified to have known clinical effects, although most of these alleles are associated with decreased enzyme activity in vitro (Torkamani, 2013).
Some of the most common thiopurine methyltransferase variants are TPM*3A, TPMP*3C, TPMP*3B, TPMP*2 and TPMP*8. TPM*3A cause nonsynonymous coding changes which are directed by exon 10 Y240C and exon 7 A154T variants while TPMP*3C and TPMP*3B have been found to contain exon 10 variant and exon 7 variant, respectively. On the other hand, TPMP*2 and TPMP*8 variants, which are associated with reduced catalytic activity in some patients have been found to be containing A80P which is a nonsynonymous variant (Torkamani, 2013).
Summary of Chapters
Introduction: Provides an overview of azathioprine's history as a chemotherapy drug and explains its mechanism in inhibiting purine synthesis to impair cellular proliferation.
Clinical Uses of Azathioprine: Details the metabolic pathways of the drug and outlines its application in treating various autoimmune diseases and preventing organ transplant rejection.
Pertinent Genetic Variability: Discusses how genetic polymorphisms, particularly in enzymes like TPMT and ITPA, influence the efficacy and clinical safety of the drug.
Functional Effect of Genetic Variability: Examines how specific mutations lead to increased levels of active metabolites, raising the risk of toxicity and myelosuppression.
Population Prevalence: Highlights the ethnic disparities in the frequency of specific thiopurine methyltransferase variants across different global populations.
Clinical Relevancy: Summarizes how pharmacogenetic insights are applied in clinical settings to manage patients with diseases such as Crohn’s and acute lymphoblastic leukemia.
Key Terms
Azathioprine, Pharmacogenetics, Thiopurine Methyltransferase, TPMT, Polymorphism, Myelosuppression, Autoimmune Diseases, 6-Mercaptopurine, Metabolic Pathways, Genetic Variability, ITPA, Alleles, Clinical Relevancy, Cytotoxicity, Immunosuppressant
Frequently Asked Questions
What is the primary focus of this research paper?
The paper focuses on azathioprine genetic polymorphisms and how variations in the human body's metabolic enzymes influence the clinical outcomes of patients receiving this treatment.
What are the central themes covered in the text?
The central themes include the mechanism of action of azathioprine, the significance of genetic variability in metabolism, ethnic prevalence of variants, and the clinical risks associated with enzyme deficiencies.
What is the main goal of the study regarding patient treatment?
The study aims to explain how identifying specific genetic variants can help prevent adverse drug reactions and guide more effective, personalized dosing strategies for patients.
Which scientific methodology is primarily addressed?
The paper utilizes a review of pharmacogenetic studies and clinical data to correlate genetic allele variants with metabolic enzyme activity and subsequent clinical drug response.
What aspects of azathioprine usage are discussed in the main chapters?
The chapters cover the history, clinical indications, biological mechanisms, genetic factors influencing toxicity, and the practical application of this data in treating autoimmune and malignant diseases.
Which keywords best characterize this research?
Key terms include Azathioprine, TPMT, Polymorphism, Myelosuppression, Pharmacogenetics, and metabolic enzyme activity.
How do TPMT variants specifically impact patient safety?
Certain TPMT variants reduce enzyme activity, leading to an accumulation of cytotoxic metabolites like 6-thioguanine, which significantly increases the risk of bone marrow suppression and other toxic effects.
Is there a connection between ethnicity and azathioprine metabolism?
Yes, research indicates that the frequency of specific genetic variants, such as TPMP*3A and TPMP*8, varies significantly across different ethnic populations, which impacts how these groups process the drug.
What is the clinical advice for patients with acute lymphoblastic leukemia (ALL)?
Due to the risk of bone marrow destruction and toxicity, medical guidelines often recommend reduced dosage or cessation of azathioprine during maintenance therapy in children with ALL.
- Quote paper
- Patrick Kimuyu (Author), 2017, Azathioprine Genetic Polymorphisms, Munich, GRIN Verlag, https://www.grin.com/document/381293
